Apellis Pharmaceuticals (APLS) files automatic mixed securities shelf
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Apellis Pharmaceuticals (APLS) Prices 9.5M Share Offering at $37/Sh
January 9, 2020 5:55 AM ESTApellis Pharmaceuticals, Inc. (NASDAQ: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the pricing of its underwritten public offering of 9.5 million shares of its common stock at a public offering price of $37.00 per share, for total gross proceeds of $351.5 million, before deducting... More
Apellis Pharmaceuticals (APLS) Announces Proposed 7M Share Common Offering
January 7, 2020 4:13 PM ESTApellis Pharmaceuticals, Inc. (NASDAQ: APLS) today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of the shares are being offered by Apellis. In addition, Apellis expects to grant the underwriters a 30-day option to... More
